Last reviewed · How we verify
Non-buffered Anesthetic
Non-buffered Anesthetic is a Local anesthetic Small molecule drug developed by University Hospitals Cleveland Medical Center. It is currently FDA-approved for Local or regional anesthesia for surgical and diagnostic procedures.
Non-buffered anesthetics work by blocking sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local or regional anesthesia.
Non-buffered anesthetics work by blocking sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local or regional anesthesia. Used for Local or regional anesthesia for surgical and diagnostic procedures.
At a glance
| Generic name | Non-buffered Anesthetic |
|---|---|
| Sponsor | University Hospitals Cleveland Medical Center |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
These agents are local anesthetics that exist in an unbuffered formulation, meaning they lack added bicarbonate or other buffering agents that would increase pH and speed onset. Non-buffered formulations have a lower pH, which can result in slower onset of action compared to buffered versions, but they remain stable without the need for added preservatives or buffers.
Approved indications
- Local or regional anesthesia for surgical and diagnostic procedures
Common side effects
- Injection site reactions
- Systemic toxicity (at high doses)
- Allergic reactions
- Methemoglobinemia (with certain agents)
Key clinical trials
- Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT (PHASE4)
- Comparative Evaluation of the Effect of pH Adjustment of the Solution of Articaine With Epinephrine on the Efficacy of Jet Anesthesia (NA)
- TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer (NA)
- aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE) (NA)
- Olfactory Biopsies (NA)
- Pain After Buffered Vs Non Buffered Articaine (PHASE2)
- Buffered Local Anesthetic (PHASE4)
- Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-buffered Anesthetic CI brief — competitive landscape report
- Non-buffered Anesthetic updates RSS · CI watch RSS
- University Hospitals Cleveland Medical Center portfolio CI
Frequently asked questions about Non-buffered Anesthetic
What is Non-buffered Anesthetic?
How does Non-buffered Anesthetic work?
What is Non-buffered Anesthetic used for?
Who makes Non-buffered Anesthetic?
What drug class is Non-buffered Anesthetic in?
What development phase is Non-buffered Anesthetic in?
What are the side effects of Non-buffered Anesthetic?
What does Non-buffered Anesthetic target?
Related
- Drug class: All Local anesthetic drugs
- Target: All drugs targeting Voltage-gated sodium channels
- Manufacturer: University Hospitals Cleveland Medical Center — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Local or regional anesthesia for surgical and diagnostic procedures
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing